4/13
10:14 am
prld
Several Insiders Invested In Prelude Therapeutics Flagging Positive News [Yahoo! Finance]
Low
Report
Several Insiders Invested In Prelude Therapeutics Flagging Positive News [Yahoo! Finance]
4/9
04:37 pm
prld
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting [Yahoo! Finance]
Low
Report
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting [Yahoo! Finance]
4/9
04:35 pm
prld
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
Low
Report
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
3/13
08:16 am
prld
Prelude Therapeutics Incorporated (NASDAQ: PRLD) is now covered by analysts at JMP Securities. They set an "outperform" rating and a $7.00 price target on the stock.
High
Report
Prelude Therapeutics Incorporated (NASDAQ: PRLD) is now covered by analysts at JMP Securities. They set an "outperform" rating and a $7.00 price target on the stock.
3/5
04:56 pm
prld
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting [Yahoo! Finance]
Low
Report
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting [Yahoo! Finance]
3/5
04:45 pm
prld
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting
Low
Report
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting
2/29
04:26 pm
prld
Prelude Therapeutics to Participate in Barclays Global Healthcare Conference [Yahoo! Finance]
Medium
Report
Prelude Therapeutics to Participate in Barclays Global Healthcare Conference [Yahoo! Finance]
2/29
04:05 pm
prld
Prelude Therapeutics to Participate in Barclays Global Healthcare Conference
Medium
Report
Prelude Therapeutics to Participate in Barclays Global Healthcare Conference
2/20
07:29 am
prld
Prelude Therapeutics Incorporated (NASDAQ: PRLD) was downgraded by analysts at HC Wainwright from a "buy" rating to a "neutral" rating. They now have a $5.00 price target on the stock.
Medium
Report
Prelude Therapeutics Incorporated (NASDAQ: PRLD) was downgraded by analysts at HC Wainwright from a "buy" rating to a "neutral" rating. They now have a $5.00 price target on the stock.
2/17
07:49 am
prld
Here's Why We're Watching Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation [Yahoo! Finance]
Medium
Report
Here's Why We're Watching Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation [Yahoo! Finance]
2/15
04:14 pm
prld
Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024 [Yahoo! Finance]
High
Report
Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024 [Yahoo! Finance]
2/15
04:05 pm
prld
Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024
High
Report
Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024
2/2
07:27 pm
prld
Prelude Therapeutics: Scientifically Interesting Oncology Company With Preclinical Data [Seeking Alpha]
Medium
Report
Prelude Therapeutics: Scientifically Interesting Oncology Company With Preclinical Data [Seeking Alpha]